The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Cristina GasparettoDuring the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Cristina Gasparetto, Duke University Cancer Center, Durham, US. In this video, she discusses the potential of selinexor combinations for relapsed/refractory multiple myeloma.
Cristina Gasparetto describes the mechanism of action of selinexor and the previous STORM study, which resulted in high toxicities. She then describes the results from the ongoing STOMP study that is comparing selinexor in combination with other backbone treatments. Dr Gasparetto describes the patient outcomes of the selinexor, dexamethasone and daratumumab arm and the selinexor, dexamethasone and carfilzomib arm. She also talks about the new dosing regimen that led to better tolerability and she concludes by discussing the response rate, progression-free survival and overall response rates.
The potential of selinexor combinations for RRMM